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Aims: Mice and non-human primates administered with 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) represent elective experimental models of 
Parkinsonism, in which degeneration of the nigro-striatal dopaminergic pathway is 
associated with prominent neuroinflammation, characterized by activated microglia and 
astrocytes in both substantia nigra (SN) and striatum. To date, it is unknown whether 
oligodendrocytes play a role in these events. 
Methods: We performed a detailed qualitative and quantitative analysis of 
oligodendrocyte-associated changes induced by acute and chronic MPTP treatment, 
in the SN and striatum of mice and macaques, respectively. Oligodendrocytes were 
immunolabeled by cell-specific markers and analyzed by confocal microscopy. 
Results: In both experimental models, MPTP treatment induces an increase in 
oligodendrocyte cell number and average size, as well as in the total area occupied 
by this cell type per tissue section, accompanied by evident morphological changes. 
This multifaceted array of changes, herein referred to as oligodendrogliosis, 
significantly correlate with the reduction in the level of dopaminergic innervation to 
the striatum. 
Conclusions: This event, associated with early damage of the dopaminergic neuron axons 
and of the complex striatal circuits of which they are part, may result in an important, 
although neglected, aspect in the onset and progression of Parkinsonism. 
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INTRODUCTION 
Parkinson’s disease (PD) is a neurodegenerative disease primarily characterized by the progressive 
degeneration of neurons of the Substantia Nigra pars compacta (SNpc) and of their fibres 
projecting to the striatum [1]. Recently, the idea that axonal damage of the SNpc neurons may 
be a critical step in PD pathology has been put forward [2,3]. Degeneration of the nigro-striatal 
fibres in human PD is irreversible and the possibility of their partial or complete regeneration is one 
of the main challenges for researchers in neurosciences. The most adopted toxin-based model of 
PD uses 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a selective dopaminergic 
neurotoxin for humans, primates and mice, which induces clinical symptoms in both humans 
and monkeys, which mimics idiopathic PD [6,7]. The neurotoxic action of MPTP begins at the 
level of the dopaminergic terminals in the striatum from where, once its metabolite MPP+ is 
captured by these terminals [8], it induces retrograde degeneration of the dopaminergic axons 
[9] that, if not impeded, leads to a dying-back of the dopaminergic neurons [3,10,11]. In the 
nervous system, maintenance of healthy axons depends on neurons, as well as on both 
myelinating and non-myelinating glial cells [12] (oligodendrocytes and Schwann cells). 
Therefore, severely injuring a neuron, or its axon, may induce axonal degeneration, damage 
to the periaxonal glial cells and, when present, progressive demyelination [13]. In several 
neurodegenerative diseases, axon damage and demyelination is followed by microglial and 
astroglial activation, which, in turn, activate oligodendrocyte precursor cells (OPCs) localized 
in the vicinity by releasing pro-inflammatory cytokines. In other neurodegenerative scenarios, 
after migration to the injured area, OPCs differentiate into mature oligodendrocytes (OLs) by 
increasing the number and complexity of their processes, up-regulating the expression of 
myelin proteins and forming new membrane wraps around axons [14-16]. Less is known on 
the behaviour of non-myelinating OLs.  
The involvement of microglial cells and astrocytes in the nigro-striatal pathway of PD A
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patients and animals with experimental Parkinsonism is a well established phenomenon [5,17,18]. 
However, apart from biochemical-based reports on the damage to OLs in the striatum after 
MPTP toxicity in mice [reviewed in 20] and the description of α-synuclein-positive inclusions in 
non-myelinating OLs of the degenerating nigrostriatal pathway of PD patients [19], the correlation 
between OL and Parkinsonism has been scarcely explored [17]. In the present work, we 
investigated in vivo whether experimental Parkinsonism induced by acute and chronic 
administration of MPTP in mice and monkeys (Macaca fascicularis), respectively, is associated 
with OL morphological changes consequent to the primary damage of the distal axon of the 
dopaminergic neurons and to the secondary alteration of the striatal circuits in which the DA 
input is integrated. 
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MATERIAL AND METHODS 
Animals and MPTP treatment 
Animals were housed and handled in the facilities of the University of Murcia in accordance with 
the norms of the states members of the European Union (2003/65/CE), the Guidelines promulgated 
by the European Convention for the protection of Vertebrate Animals used for Experimental and 
other scientific purposes of the Council of Europe (no. 123, June 15th, 2006), the European 
Communities Council Directive 2010/63/ECC, and by the National Institutes of Health Guide for 
the Care and Use of Laboratory Animals (NIH Guide, revised 1996). The experimental procedures 
and protocols were approved by the Ethical Committee for Animal Research of the University of 
Murcia. All efforts were made to minimize animal suffering and to reduce the number of animals 
used and to utilize alternatives to in vivo techniques. 
MPTP treated mice 
Three-month-old C57BL/6J male mice (Jax®Mice, The Jackson Laboratory, Bar Harbor, Maine 
USA) received four intraperitoneal injections of MPTP-HCl (Sigma- Aldrich, St. Louis, MO, USA) 
dissolved in 0.9% NaCl (20 mg/kg) at 2 hours (hrs) intervals according to established protocols 
[21]. Control animals received saline injections. Four (TH analysis) to five (confocal quantitative 
analysis) mice were used for each experimental group. 
Parkinsonian macaques 
We used brain sections derived from a colony of chronic parkinsonian macaques (Macaca 
fascicularis), previously established and studied in our Primate Unit. Analyzed samples were 
obtained from seven young adult animals: four of the seven monkeys had been treated weekly with 
low intravenous doses of MPTP (0.3 mg/kg) and progressive motor alterations were assessed using 
a rating scale ranging from 0 to 25, as previously described [5]. MPTP-intoxicated monkeys 
showing clear impairment of their motor score were classified as parkinsonian; untreated animals A
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were considered as controls.  
 
Immunohistochemistry and immunofluorescence 
Antibodies 
Antibodies used were: sheep anti-Tyrosine Hydroxylase antibody (TH) (1:1000, Chemicon, 
Temecula, CA, USA); mouse anti-Myelin Basic Protein (MBP), diluted 1:30000 (Chemicon, Clone 
NS-1, Cat. MAB1580), which detect early and mature oligodendrocytes in mouse brain 
sections [22], rat anti-2-3-cyclic nucleotide 3-phosphodiesterase (CNPase) (1:200, Abcam 
Cambridge, UK), and rat anti-MBP, diluted 1:100 (Chemicon, Cat. MAB395), which detects 
mature oligodendrocytes in monkey brain sections. 
Tissue preparation from mice 
Mice for each of the following experimental categories were used: control, 72 hours (hrs) and 2 
weeks (wks) after the last MPTP injection. Mice were deeply anesthetized with an intraperitoneal 
injection of ketamine (50 mg/Kg body weight, b.w.) and xylazine (50 mg /Kg b.w.) and perfused 
transcardially with a Ringer’s oxygenated solutions (pH 7.3), followed by a fixative composed 
by 4% freshly depolymerized paraformaldehyde in phosphate buffer (PB). Brains were 
dissected and cryoprotected, for 72 hrs at 4 °C, in 30% sucrose in saline until they sank. Free-
floating coronal sections of 25 µm-thick, spanning the entire midbrain and striatum, were cut 
at a cryostat and stored at -20 °C in a cryoprotectant composed by 0.5 M sucrose diluted in 
ethylene glycol and 0.2 M PB (pH 7.4) in a 1:1 proportion.  
Tissue preparation from macaques 
Two years after the last MPTP administration, monkeys were sacrificed with a lethal injection of 
pentobarbital after a pre-anaesthesia with an intramuscular injection of ketamine (8 mg/Kg b.w.). 
Brains were quickly removed, fixed for 3 days in 4% freshly depolymerized paraformaldehyde in 
0.1 M PB and cut into 40 µm-thick coronal sections at a sliding microtome (Microm, HM400). A
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Immunohistochemistry and immunofluorescence 
Brain sections were processed for TH immunohistochemistry by using the avidin-biotin 
complex (ABC) procedure. The primary antibody was diluted in 1% normal horse serum 
(NHS), 0.5% Triton X-100 and 0.1% NaN3 in phosphate buffered saline (PBS) (pH 7.4), for 48 
hrs at 4°C, under constant shaking. After a rinse in buffer, sections were first incubated with 
a biotinylated donkey anti-sheep IgG secondary antibody (diluted 1:500, Jackson Immuno 
Research Laboratories, Inc.), and successively with the ABC, diluted 1:100 (ABC kit; 
Vectastain Elite, Vector Labs, Burlingame, CA, USA). The peroxidase activity associated with 
the immune complexes was revealed by incubating the sections in 0.25 mg/ml 3,3’-
diaminobenzidine (DAB) (Sigma-Aldrich) and 0.03% H2O2 (Sigma-Aldrich) in PBS, pH 7.4. 
Some of the mouse brain sections immunolabeled for MBP were also processed with the ABC 
immunohistochemistry, using as the secondary antibody a biotinylated donkey anti-mouse 
IgG. The following procedures were similar to those described above. Negative controls were 
obtained by omitting the primary antibodies. Floating sections were mounted on gelatin-
coated slides and dehydrated in an ascending series of ethanol alcohol and xylene before being 
coverslipped.  
MBP in mice and macaques was localized by immunofluorescence, using as a secondary 
antibody a goat anti-mouse IgG and a goat anti-rat IgG, respectively, combined with Alexafluor 594 
or Alexafluor 488 (1:1000, Molecular Probes, Carlsbad, CA, USA). Cell nuclei were counterstained 
with DAPI (1:1000, Molecular Probes, Carlsbad, CA, USA). Sections were mounted on glass 
slides, coverslipped with the ProLong® Gold Antifade reagent (Molecular Probes) and viewed at a 
Leica DMIRE2 confocal microscope (Leica Microsystems, Exton, PA, USA). Acquired images 
were processed with the Leica Confocal Software (Leica Microsystems, Heidelberg 19 GmbH). 
Quantitative analysis on immunohistochemical sections 
Quantification of immunopositive cells in the SNpc was performed on two coronal sections from A
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each monkey (+1 mm and +2 mm from the anterior commisure according to macaque brain 
atlas) and three coronal sections (0.86 mm, -046 mm, and -3.08 mm from Bregma according to 
mouse brain atlas) from each mouse. Images of the SNpc and striatum from both hemispheres 
were acquired, by using a 20X objective, at a light microscope (Zeiss Axioplan2) connected to a 
digital camera (AxioCam HRc, Zeiss). TH-immunopositive (TH+) cells were counted in each 
photographic field and expressed as the mean number of cells/mm2
 
± the standard error of the 
mean (SEM). Specifically, each photographic field corresponds to 260 x 370 µm sided 
rectangles and all cells, including those falling at the border of the photographic rectangle, 
were counted. TH immunoreactivity in the striatum was evaluated by densitometric analysis of the 
immunopositive areas and expressed as optical density (OD, arbitrary gray units), calculated in 
relation to the background staining of each section by using the ImageJ software (Burger and 
Burge, Springer Verlag). 
Quantitative analysis on confocal microscope images 
Brain sections were examined by using immersion oil 63X objective. Each section was scanned in 
0.5 µm-thick optical section, the series range being determined by setting the upper and the lower 
thresholds with the Z/Y Position for Spatial Image Series setting. All quantifications were done 
blindly. Images were converted into black and white by using the Image-J software and number and 
area occupied by the immunopositive cells in each photographic field (three image stacks per 
animal taken through the whole thickness of the SNpc and striatum) was measured. 
Statistical analysis 
Statistical analyses were performed by using either the Student's t test (when comparing two 
groups at a time), or the one-way ANOVA test following the post-hoc Dunnet's analysis (when 
comparing multiple groups against a single reference group). Differences were considered 
statistically significant for p ≤ 0.05. Data were expressed as the mean ± the standard error of 
the mean (SEM). A Pearson coefficient was used to establish the correlation analysis. The A
cc
ep
te
d 
A
rti
cl
e
© 2012 The Authors 
Neuropathology and Applied Neurobiology © 2012 British Neuropathological Society 
significance of the correlations was determined by using the critical values of the Pearson 
coefficient table. Differences were considered statistically significant for p < 0.05. 
  
 
 
 
RESULTS 
Loss of dopaminergic neurons and axons induced by MPTP treatment in mice is associated with a 
transient oligodendrogliosis in both SNpc and striatum 
We performed detailed confocal and quantitative analysis on sections of striatum and SNpc 
immunolabeled for MBP, to evaluate changes in cell number, morphology and area of occupancy 
in MPTP-treated mice compared to control (Fig. 1). Seventy-two hours after MPTP injection, a 
significant increase in the MBP+ cell number/mm2; (SNpc: control = 205.2 ± 35.4, 72 h MPTP = 
537.0 ± 20.9; striatum: control = 425.9 ± 28.6, 72 h MPTP = 714.2 ± 22.2), mean cell size in 
(SNpc: control = 26.1 ± 1.3 µm2, 72 h MPTP = 76 ± 3.7 µm2; striatum: control = 21.6 ± 1.7 
µm2, 72 h MPTP = 183.9 ± 60.6 µm2), and total area occupied by OLs per photographic field 
(which corresponds to 96,200 µm2) (SNpc: control = 997.1 ± 95.5 µm2, 72 h MPTP = 2920 ± 
678.5 µm2; striatum: control = 535.6 ± 164.2 µm2, 72 h MPTP = 7650.5 ± 2316.8 µm2) was 
observed (Fig. 1A,B and 1D-F, SNpc; Fig. 1A’,B’ and 1D’-F’, striatum). To date, this is the 
first quantitative evaluation, which takes into account this set of parameters in MPTP-treated 
mice and macaques for evaluating alteration of the normal steady-state condition of OLs. OLs 
were characterized by hypertrophic cell bodies, thickened proximal processes and elevated 
arborization of the distal ones (Fig. 1A,A’, control; Fig. 1B,B’, 72 hrs MPTP), which accounted for 
the noticeable enlargement of their cell body size (Fig. 1E,F, SNpc; Fig. 1E’,F’, striatum). Two 
weeks after MPTP treatment, confocal (Fig. 1C,C’) and quantitative (Fig. 1D,F and 1D’,F’) A
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analyses showed a significant decrease, with respect to the 72 hrs, in the number of immunopositive 
cell/mm2 in both SNpc (72 h MPTP= 537.0 ± 20.9, 2 wks MPTP= 383.1 ± 15.4) (Fig. 1C and 1D-
F) and striatum (72 h MPTP= 714.2 ± 22.2, 2 wks MPTP= 350.1 ± 17.2) (Fig. 1C’ and 1D’-F’). 
Except for the number of the MBP+ cells in the SNpc and their average area they occupied in the 
striatum, all these parameters were also significantly lower than, or equal to, those measured in 
control animals, suggesting a reversion of this process. These results were confirmed by camera 
lucida reconstructions of anti-oligodendrocyte immunopositive cells, revealed with DAB (Fig. 
2A1,2,3), performed on sections of control and MPTP-treated mouse striatum. As expected, 72 hrs 
after MPTP treatment, a significant decrease in both cell number/mm2 (control = 228.83 ± 10.39, 
72h MPTP = 98.66 ± 5.84) and intensity of immunolabeling of TH+ neurons and neurites in the 
SNpc, as well as in the intensity of the TH-immunopositivity in the striatum, expressed as OD 
(control = 22.06 ± 3.13, 72h MPTP = 9.58 ± 2.89), were observed (Supplementary Fig. 1). This 
decrease partially, but significantly, recovered 2 wks after MPTP injection. OL phenotypical 
changes inversely correlated with the levels of TH immunoreactivity along the dopaminergic 
pathway, i.e. a higher degree of dopaminergic loss was associated with higher levels of 
oligodendrogliosis (Fig. 2B). 
 
 
Persistent oligodendrogliosis characterizes the striatum of parkinsonian macaques two years after 
MPTP treatment 
Since in mice the most prominent oligodendrogliosis was observed in the striatum, a confocal 
and quantitative analysis was carried out on sections of macaque striatum immunolabeled for MBP 
(Fig. 2). Chronic Parkinsonian macaques showed a striking and significant increase in the number 
of MBP+ cells in both caudate (Fig. 2B,B’, confocal images; Fig. 2C, cell count: ctrl = 43.02 ± 3.6 
and MPTP = 94 ± 10.3 MBP+ cells per mm2) and putamen (Fig. 2G,G’, confocal images; Fig. A
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2H, cell count, ctrl = 224.07 ± 15.9 and MPTP 540.12 ± 41.01 MBP+ cells per mm2) with respect 
to control. This increase was also appreciated by using DAB as the revelation system in place of 
fluorescence (Fig. 2A1,2 caudate; Fig. 2F1,2 putamen). OLs in macaque striatum also showed an 
apparent increase in their cell body size, which, however, we were technically unable to measure 
as cell processes were so intermingled that the software could not identify individual cells. After 
MPTP treatment, the number of MBP+ cells in both caudate and putamen inversely correlated with 
the number of surviving dopaminergic neurons in the SNpc (Figs. 2D,I) and with the densitometric 
values corresponding to the amount of TH+ fibers projecting into both areas of the striatum (Fig. 
2E,J). Chronic macaque MPTP treatment elicited a marked decrease in TH+ cells and neurites in the 
SNpc, as well as in the dopaminergic projections to the striatum (Supplementary Fig. 2). However, 
differently from mice, these parameters were persistent 2 years after the last MPTP injection. 
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DISCUSSION 
Our results demonstrate that loss of dopaminergic neurons and of their axons projecting to the 
striatum, which is consequent upon MPTP-induced Parkinsonism in mice and macaques, is 
accompanied by a prominent oligodendrogliosis along the nigro-sriatal pathway. 
In mice, acute MPTP administration triggers a significant OL response within 72 hrs. This 
event is exacerbated in the striatum, possibly connected with the fact that MPP+, the toxic product 
of MPTP metabolism in glial cells [23], is captured by the dopaminergic axon terminals and 
retrogradely transported to the cell body, affecting neuron activity and viability [9]. This 
mechanism of retrograde degeneration is not peculiar to MPTP, as it is also observed in other 
pathological conditions induced by administration of different neurotoxins [24,25]. The idea that, at 
least in some of the common neurodegenerative pathologies, deregulation of axonal activity could 
be primary with respect to cell body damage and neuron death is interesting, if considering that in 
both human PD and animal model of Parkinsonism, axons are severely affected [26,27]. In fact, it 
has been hypothesized that axonal degeneration, probably involving OLs, may indeed precede 
protein aggregation in nerve fibres (Lewy neurites) and neuronal apoptosis, becoming one of the 
initial causes of neuronal loss [28]. In our experimental model, oligodendrogliosis may reflect 
different degrees of axonal damage consequent upon MPTP administration, as previously shown by 
ultrastructural studies [29]. The anti-oligodendrocyte antibody we used to recognize OLs labels 
both early and mature OLs. This means that myelinating and non-myelinating cells can be 
equally immunolabeled. Based on our correlation studies, showing higher levels of 
oligodendrogliosis when the MPTP-induced loss of the dopaminergic innervation to the 
striatum is more prominent, we suggest that the first OL response is in part a consequence of 
the direct lesion of the dopaminergic neuron axons, which are none or scarcely myelinated in 
different species, including humans [30-33]. On the other hand, we envision that striatal spiny 
neurons, deprived of the dopaminergic input, may undergo a series of changes characteristic A
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of the neuronal response to denervation. These imply also the remodeling of their own axons, 
as well alteration of other inputs impinging on their cell body and coming, for instance, from 
the cortical layers (represented by highly myelinated axons). This hypothesis is supported by 
numerous studies demonstrating how the striatum responds to fluctuation in dopaminergic 
signaling and how diseases that alter this signaling change striatal functions [reviewed in 34]. 
An intense and bidirectional cross-talk between glia and axons has been demonstrated both 
during development [34,35] and in adulthood [34]. Specifically, while glia maintain 
axolemmal organization, axonal diameter and neuron health, axons maintain glial 
differentiation and, when present, myelin integrity [34], by means of axonal contact, diameter, 
electrical activity and different types of molecular signaling [reviewed in 14]. In the 
peripheral nervous system, altering this signaling by axonal damage initiates an active 
Schwann cell re-programming [36]. A similar mechanism can, therefore, be advocated in the 
central nervous system, where damage to axonal transport and neuron physiology, 
characteristic of dying-back pathologies (here mimicked by MPTP administration), influences 
OL activity and myelinating properties.  On the other hand, one should consider that 
cytokines released by both microglia and astrocytes, involved in a parallel inflammatory 
process [5,17,manuscript in preparation], may also contribute to exacerbating an OL 
response.  
A question arising from our results is whether the features we described are due to 
effective OL morphological changes, or are just a representation of a relocalization of the 
MBP protein within the cells. It has been reported that mature non-myelinating OLs, 
identified as MBP+ cells, are characterized by a highly ramified morphology, which is reduced 
when the formation of new wraps around nearby axons, to form myelinated internodes, occur 
[37,38]. These data strongly support the hypothesis that, in our experimental paradigm, 
axonal degeneration induced by MPTP triggers the shift to an MBP+-highly ramified-non-A
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myelinating OL phenotype, which will be reverted with the restoration of peri-axonal wraps. 
To further investigate this hypothesis, we performed a double immunostaining for MBP and 
2-3-cyclic nucleotide 3-phosphodiesterase (CNPase), a protein expressed in myelin-forming 
cells throughout their lineage, in the striatum of control mice. Interestingly, in contrast to 
what is reported in the mouse cortex, where CNPase is localized in both cell bodies and 
processes and MBP is mostly present in cell processes [39] in the mouse striatum MBP 
immunostaining overlapped that of CNPase (Supplementary Fig. 3). This result does not 
allow addressing the idea of a putative change in the distribution of MBP after MPTP 
treatment. However, we cannot exclude the possibility that, beside OL morphological 
changes, a general increase in MBP immunoreactivity after the MPTP treatment could also 
occur. 
Two weeks after acute MPTP administration in mice, the partial recovery in TH 
immunoreactivity and the reduction in the inflammatory response [manuscript in 
preparation]
 
in both SNpc and striatum was concomitant to the reduction of 
oligodendrogliosis, suggesting that re-establishment of some dopaminergic connectivity 
reflects a more general restoration of striatal circuitry. This result opens up an important 
avenue of investigation concerning OL behaviour, i.e. their possible involvement in the 
remodeling and guidance of distal axons of those dopaminergic neurons that survived MPTP 
treatment, as well as of other neuron axons projecting to the striatum and affected by the 
disruption of the nigro-striatal circuit. Recurrent OL activation is a peculiar feature of 
demyelinating diseases, a potentiality that is, however, decreased during aging [40]. As idiopathic 
PD is a pathology characteristic of the elderly, a decrease in axon plasticity and re-myelination 
capabilities with age may indeed further exacerbate progressive neuronal death. To corroborate 
this hypothesis, future studies on aged mice could give precious information on the 
development of Parkinsonism by combining both the pathological aspect and the A
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physiological aging.  
The results obtained in the macaque model of chronic MPTP administration differ, but 
do not contradict, those described in mice. In chronic parkinsonian macaques, both number and 
size of OLs in the striatum were still significantly higher than in control animals two years after 
neurotoxin administration, the oligodendrogliosis being more prominent in macaques suffering 
more severe dopaminergic depletion. Oligodendrogliosis was maintained throughout the years and 
no apparent recovery of the dopaminergic system was observed. This discrepancy in the time of 
occurrence of oligondendrogliosis between mice and macaca, could be partly due to species 
differences. Moreover, differently from MPTP acutely-treated mice, in chronically-induced 
Parkinsonism, the presence of a cascade of glia-mediated inflammatory signals, perpetuating 
themselves, has been well established [5]. These could sustain a persistent oligodendrogliosis 
involving both myelinating and non-myelinating OLs, both expressing MBP [41]. This 
prolonged inflammatory response may also promote a glial scar, creating a hostile environment in 
which OL activity could be ineffective compared with acute lesions. As discussed for mice, 
oligodendrogliosis may not be solely associated with degeneration of dopaminergic neuron 
axons, as spiny neurons and neuronal populations projecting to the striatum, may undergo 
progressive degeneration, triggering and perpetuating oligondendrogliosis.  
In conclusion, this study underlines that OLs may play an important role in 
Parkinsonism, although the function and mechanisms in experimental models and the human 
disease need to be further investigated. Detailed post mortem studies of the nigro-striatal pathway 
of PD patients will be crucial for understanding type and extent of axonal modifications occurring 
during the development of the disease, as well as for developing specific therapeutic strategies 
aimed at preventing, or minimizing, axonal degeneration in Parkinsonism. 
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FIGURE LEGENDS 
Figure 1. Transient OL activation in both SNpc and striatum of MPTP treated mice. (A-C, 
A’-C’) Confocal analysis of oligodendrocyte immunolabeling (red) in the SNpc and striatum of 
control (A,A’) and MPTP-treated mice (B,B’, 72 hrs; C,C’, 2 wks). Seventy-two hours after MPTP 
injection (B,B’), a prominent OL activation is observed compared with control animals (A,A’). 
Oligodendrogliosis drastically reduces after 2 wks (C,C’). Cell nuclei are counterstained in blue 
with DAPI. (D-F; D’-F’) Quantitative analysis shows that OL cell number (D, SNpc and D’, 
striatum) and average cell body size (E, SNpc and E’ striatum) significantly increase, respect to 
control mice, 72 hrs after MPTP treatment. A similar increase is observed in the total area occupied 
per section by the immunopositive cells (F, SNpc, F’, striatum). All these values fall 2 wks after 
MPTP treatment. n= 4-5 animals/group. Histograms represent the mean ± SEM; *p < 0.05, 
calculated by one-way ANOVA followed by the post hoc Duncan’s test. Analyzed areas are 
encircled in red on the brain section drawings at the left hand side.  
 
Figure 2. Correlation analysis between oligodendrogliosis and TH immunolabeling in the 
SNpc and striatum of MPTP-treated mice. (A) MBP immunolabeling with the avidin-biotin-
DAB method clearly shows the changes, compared with the control (1), occurring in OL 
morphology 72 hrs (2) and 2 wks (3) after MPTP treatment, also exemplified in the camera lucida 
drawings. (B) Increase in number (1, 2 and 1’, 2’), mean (3, 4 and 3’, 4’) and total area (in µm2) (5, 
6 and 5’, 6’) occupied per section by the oligodendrocyte-immunopositive cells inversely correlate 
to the levels of TH immunostaining in both SNpc and striatum. These correlations refer to the 
number of TH+ cells in the SNpc (1, 3, 5 and 1’, 3’ 5’) and the optical density of the TH+ fibers in 
the striatum (2, 4, 6 and 2’, 4’, 6’). The Pearson correlation coefficient R2 and the corresponding p 
values are indicated in each correlation graph. n = 15-20. 
 
Figure 3. Persistent OL activation in the striatum of parkinsonian monkeys. 
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Caudate (A) and putamen (F) in the monkey brain are put into evidence by the red boxes in the 
drawings at the left hand side. On the right of each drawing, details of MBP immunolabeling in the 
striatum of control and MPTP-treated monkeys, revealed by the avidin-biotin-DAB method, are 
shown (1, 2). The toxic treatment induces an increase in the area occupied by immunopositive cell 
processes in both caudate (A) and putamen  (F). The corresponding confocal analysis is shown in 
(B,B’) for the caudate and in (G,G’) for the putamen. A striking increase, with respect to control 
(B,G), in MBP immunolabeling (red) is still observed two years after MPTP treatment (B’,G’). Cell 
nuclei are counterstained in blue with DAPI. (C,H) Quantitative analysis conducted on the confocal 
images reveals a significant increase in the number of OLs in both the caudate (C) and putamen (H) 
of parkinsonian monkeys compared with control animals. (D,E; I,J) The increase in MBP+ cells 
inversely correlate with the number of TH+ neurons counted in the SNpc (D, caudate; I, putamen) 
and with the optical density (O.D.) values of the TH immunolabeling of the dopaminergic axons 
projecting to caudate (E) and putamen (J). Control group: n = 3 monkeys; parkinsonian group: n = 5 
monkeys. The histograms in C and H represent the mean ± SEM; ***p < 0.001, calculated by the 
Student’s t test. The Pearson correlation coefficient, R2, is indicated in each of the correlation 
graphs (D,E,I,J). 
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SUPPLEMENTARY FIGURE LEGENDS 
Supplementary Figure 1. TH depletion and partial recovery in both SNpc and striatum 
following acute MPTP treatment in mice. TH-DAB immunostaining in the SNpc (A-C) and 
striatum (D-F) of control (A and D) and MPTP-injected mice (B,C,E,F). (A,D) In control animals, 
TH immunolabeling is intense in both cell bodies and axons of the dopaminergic neurons. (B,E) 
Seventy-two hours after MPTP treatment, a drastic decrease in the intensity and number of 
immunopositive neurons and neurites in the SNpc (B), as well as in the intensity of TH-
immunolabeling in the whole striatum, is observed, especially in the dorso-lateral area. (C,F) Two 
weeks after MPTP injection, a partial recovery of the immunolabeling is observed in both areas (C, 
SNpc; F, striatum). (G,H) Quantitative analysis confirms that changes observed 72 hrs and 2 wks 
after MPTP injection, with respect to the control (ctrl), in both the number of TH+ cells/mm2 in the 
SNpc (G) and the optical density of the TH+ fibers in the striatum (H) are statistically significant. A 
partial, but significant, recovery is observed 2 wks after the MPTP treatment in both SNpc and 
striatum. n = 4-5 animals/time point; bars represent the mean ± SEM; *p < 0.05, calculated by one 
way ANOVA and Duncan test. 
 
Supplementary Figure 2. Persistent TH depletion induced by MPTP chronic treatment in 
monkeys. (A,B) TH-DAB immunolabeling in the SNpc (A1,2) and striatum (B1,2), both caudate 
(Cd) and putamen (Put), of control (A1 and B1) and parkinsonian monkeys (A2 and B2), shows a 
marked decrease in TH+ cells and neurites in the SNpc (area circled in red in the left hand drawing) 
and dopaminergic projections to the striatum (area circled in red in the left hand drawing) in 
parkinsonian macaques 2 years after the last MPTP injection, compared to control. (C) 
Quantification of the number of TH+ cells in the SNpc and measurement of the optical densities 
(O.D.) of the TH+ immunopositive fibers in the striatum show that these decreases are statistically A
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significant. Control group: n = 3 monkeys; Parkinsonian group: n = 5 monkeys. Histograms 
represent the mean ± SEM; *p < 0.05, **p < 0.01 calculated by Student’s t test. 
Supplementary Figure 3. CNPase and MBP co-labeling in the mouse nigro-striatal pathway. 
Top row of confocal images show a mouse striatum immuno-stained for CNPase (red) and MBP 
(green). An intense immunostaining for both proteins decorates cell bodies (high magnifications are 
shown in the top row inserts together with the lateral view along the z axis) and fibers coming 
from the cortex and crossing the striatum. Fibers of the nigro-striatal pathway also co-label for 
CNPase and MBP (bottom row magnifications). DAPI staining (blue) was used to label nuclei. 
Scale bars: 50 µm in the top row, 5 µm in the insert, and 10 µm in the bottom row.  
A
cc
ep
te
d 
A
rti
cl
e
© 2012 The Authors 
Neuropathology and Applied Neurobiology © 2012 British Neuropathological Society 
Figure 1 
 
A
cc
ep
te
d 
A
rti
cl
e
© 2012 The Authors 
Neuropathology and Applied Neurobiology © 2012 British Neuropathological Society 
Figure 2 
 
A
cc
ep
te
d 
A
rti
cl
e
© 2012 The Authors 
Neuropathology and Applied Neurobiology © 2012 British Neuropathological Society 
Figure 3 
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